Survey of depot antipsychotic prescribing in southern Adelaide

REFERENCES

• Jablensky A, McGrath J, Herrman H, et al. Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Australian and New Zealand Journal of Psychiatry 2000; 34: 221–236
   PubMed Web of Science ®Google Scholar
• Adams C E, Fenton M KP, Quraishi S, David A S. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 2001; 179: 290–299
   PubMed Web of Science ®Google Scholar
• Castle D, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients’ perspective. Australian and New Zealand Journal of Psychiatry 2002; 36: 633–641
   PubMed Web of Science ®Google Scholar
• Walburn J, Gray R, Gournay K, Quraishi S, David A S. Systematic review of patient and nurse attitudes to depot antipsychotic medication. British Journal of Psychiatry 2001; 179: 300–307
   PubMed Web of Science ®Google Scholar
• Kane J M, Aguglia E, Altamura A C, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology 1998; 8: 55–66
   PubMed Web of Science ®Google Scholar
• Barnes T RE, Curson D A. Long term depot antipsychotics: a risk–benefit assessment. Drug Safety 1994; 10: 464–479
   PubMed Web of Science ®Google Scholar
• Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. International Clinical Psychopharmacology 1995; 9(Suppl. 5)S17–S20
   PubMed Web of Science ®Google Scholar
• Keks N A, Altson K, Hope J, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Australian and New Zealand Journal of Psychiatry 1999; 33: 896–901
   PubMed Web of Science ®Google Scholar
• Alexopoulos G S. Lack of complaints in schizophrenicswith tardive dyskinesia. The Journal of Nervous and Mental Disease 1979; 167: 125–127
   PubMed Web of Science ®Google Scholar
• Menzies V, Farrell S P. Schizophrenia, tardive dyskinesia, and the Abnormal Involuntary Movement Scale (AIMS). Journal of the American Psychiatric Nurses Association 2002; 8: 51–56
   Google Scholar
• Munetz M R, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hospital and Community Psychiatry 1988; 39: 1172–1177
   PubMedGoogle Scholar
• Ahrens T N, Sramek J J, Herrera J M, Jewett C M, Alcorn V E. Pharmacy-based screening program for tardive dyskinesia. Drug Intelligence and Clinical Pharmacy 1988; 22: 205–208
   Google Scholar
• Newcomer J W, Haupt D W, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry 2002; 59: 337–345
   PubMed Web of Science ®Google Scholar
• Lindenmayer J, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry 2003; 160: 290–296
   PubMed Web of Science ®Google Scholar
• Humberstone V, Wheeler A, Lambert T. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Australian and New Zealand Journal of Psychiatry 2004; 38: 240–245
   PubMed Web of Science ®Google Scholar
• Kane J M, Eerdekens M, Lindenmayer J, Keith S J, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. The American Journal of Psychiatry 2003; 160: 1125–1132
   PubMed Web of Science ®Google Scholar
• Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 2005; 39: 1–30
   PubMed Web of Science ®Google Scholar
• Carpenter W T, Buchanan R W, Kirkpatrick B, Lann H D, Breier A F, Summerfelt A T. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. American Journal of Psychiatry 1999; 156: 412–418
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association Task Force on Tardive Dyskinesia. Tardive Dyskinesia: a Task Force Report of the American Psychiatric Association. American Psychiatric Association, Washington, DC 1992
   Google Scholar
• Yassa R, Jeste D V. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bulletin 1992; 18: 701–715
   PubMed Web of Science ®Google Scholar
• Woerner M G, Kane J M, Lieberman J A, et al. The prevalence of tardive dyskinesia. Journal of Clinical Psychopharmacology 1991; 11: 34–42
   PubMed Web of Science ®Google Scholar
• Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale schizophrenia surveys 23: movement disorders. British Journal of Psychiatry 2002; 181: 422–427
   PubMed Web of Science ®Google Scholar
• Byne W, White L, Parella M, Adams R, Harvey P D, Davis K L. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. International Journal of Geriatric Psychiatry 1998; 13: 473–479
   PubMed Web of Science ®Google Scholar
• Hope J D, Keks N A, Sacks T L, Freer T. Abnormal involuntary movements in people with schizophrenia in the community. The Medical Journal of Australia 1999; 171: 111–112
   PubMedGoogle Scholar
• Munetz M R, Roth L H. Informing patients about tardive dyskinesia. Archives of General Psychiatry 1985; 42: 866–871
   Google Scholar
• Gupta S, Frank B, Madhusoodanan S. Tardive dyskinesia: legal issues and consent. Psychiatric Annals 2002; 32: 245–248
   Google Scholar
• Haupt D W, Newcomer J W. Hyperglycemia and antipsychotic medications. The Journal of Clinical Psychiatry 2001; 62(Suppl. 27)S15–S26
   PubMedGoogle Scholar
• Kornegay C J, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom General Practice Research Database. The Journal of Clinical Psychiatry 2002; 63: 758–762
   PubMed Web of Science ®Google Scholar
• Dwyer D S, Bradley R J, Kablinger A S, Freeman A M. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Annals of Clinical Psychiatry 2001; 13: 103–113
   PubMedGoogle Scholar
• Ryan M CM, Collins P, Thakore J H. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. American Journal of Psychiatry 2003; 160: 284–289
   PubMed Web of Science ®Google Scholar
• Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional neuroleptic medications. The Journal of Clinical Psychiatry 1998; 59: 294–299
   PubMed Web of Science ®Google Scholar